Yes. No more of this Fusilev generic competition overhang. As a future potential play p-e ratios don't matter. So forget about the past and look ahead and look at the value of the pipeline. All you spineless bashers and "Frank"ensteins, get lost.
As usual you make a great point Thoughtful. The company's strategy should now be (and I hope will be) to refocus the market on the pipeline. That will not only require judicious additions to the pipeline like the ones they announced today, but also craft a communication strategy that will make the market look at this company as a new drug pipeline company and not as a stodgy old company competing with generics for some market share crumbs. Look at ARIA for God's sake. For a small growth company this kind of p/e focus is a total distraction. Goddammit management, move away from that!!!!
Funniest thing....NOT REALLY.....but I saw a pharma company drop to the 7's right before it was bought out last year. Can't remember who it was, but it was in January and it wasn't HGSI!! You never know about these humongous drops!!! MM's and fraudsters do all kinds of wicked and unscrupulous things to make money!